Kazia Therapeutics Ltd
KZIA10.870USD
+0.890+8.92%
收盘 12/19, 16:00（美东）报价延迟15分钟
87.98M总市值
亏损市盈率 TTM
关于 Kazia Therapeutics Ltd 公司
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd简介
公司代码KZIA
公司名称Kazia Therapeutics Ltd
上市日期Sep 01, 1994
CEOFriend (John E)
员工数量- -
证券类型Depository Receipt
年结日Sep 01
公司地址Three International Towers Level 24,
城市SYDNEY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Australia
邮编2000
电话1161298780088
网址https://www.kaziatherapeutics.com/
公司代码KZIA
上市日期Sep 01, 1994
CEOFriend (John E)
Kazia Therapeutics Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
单位: USD更新时间: 3月4日 周二
单位: USD更新时间: 3月4日 周二
FY2022
FY2021
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Alumni Capital Management LLC
0.26%
Barclays Capital Inc.
0.22%
Rockefeller Capital Management
0.10%
其他
97.03%
持股股东
持股股东
占比
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Alumni Capital Management LLC
0.26%
Barclays Capital Inc.
0.22%
Rockefeller Capital Management
0.10%
其他
97.03%
股东类型
持股股东
占比
Individual Investor
1.39%
Investment Advisor
1.24%
Investment Advisor/Hedge Fund
0.27%
Research Firm
0.23%
其他
96.88%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
38
172.48K
10.65%
+130.03K
2025Q2
38
284.07K
17.55%
+238.97K
2025Q1
39
31.11K
2.29%
-13.78K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Chernett (Jorey)
137.20K
8.48%
+137.20K
--
Jun 11, 2025
Dauntless Investment Group, LLC
115.77K
7.15%
+115.77K
--
Jun 30, 2025
Alumni Capital Management LLC
28.41K
1.75%
+28.41K
--
Sep 12, 2025
Barclays Capital Inc.
24.00K
1.48%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
2.83K
0.18%
-2.42K
-46.07%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
公告日期
类型
比率
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
常见问题
Kazia Therapeutics Ltd的前五大股东是谁？
Kazia Therapeutics Ltd 的前五大股东如下：
Chernett (Jorey)持有股份：137.20K，占总股份比例：8.48%。
Dauntless Investment Group, LLC持有股份：115.77K，占总股份比例：7.15%。
Alumni Capital Management LLC持有股份：28.41K，占总股份比例：1.75%。
Barclays Capital Inc.持有股份：24.00K，占总股份比例：1.48%。
UBS Financial Services, Inc.持有股份：2.83K，占总股份比例：0.18%。
Chernett (Jorey)持有股份：137.20K，占总股份比例：8.48%。
Dauntless Investment Group, LLC持有股份：115.77K，占总股份比例：7.15%。
Alumni Capital Management LLC持有股份：28.41K，占总股份比例：1.75%。
Barclays Capital Inc.持有股份：24.00K，占总股份比例：1.48%。
UBS Financial Services, Inc.持有股份：2.83K，占总股份比例：0.18%。
Kazia Therapeutics Ltd的前三大股东类型是什么？
Kazia Therapeutics Ltd 的前三大股东类型分别是：
Chernett (Jorey)
Dauntless Investment Group, LLC
Alumni Capital Management LLC
Chernett (Jorey)
Dauntless Investment Group, LLC
Alumni Capital Management LLC
有多少机构持有Kazia Therapeutics Ltd(KZIA)的股份？
截至2025Q3，共有38家机构持有Kazia Therapeutics Ltd的股份，合计持有的股份价值约为172.48K，占公司总股份的10.65%。与2025Q2相比，机构持股有所增加，增幅为-6.89%。
哪个业务部门对Kazia Therapeutics Ltd的收入贡献最大？
在FY2022，--业务部门对Kazia Therapeutics Ltd的收入贡献最大，创收--，占总收入的--%。
